{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T16:27:20Z","timestamp":1788193640226,"version":"build-2803163510"},"reference-count":118,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T00:00:00Z","timestamp":1620086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T00:00:00Z","timestamp":1620086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"CSIR - Indian Institute of Chemical Technology"},{"DOI":"10.13039\/100009526","name":"Amrita Vishwa Vidyapeetham University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009526","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neuromol Med"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s12017-021-08660-4","type":"journal-article","created":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T16:03:05Z","timestamp":1620144185000},"page":"449-465","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Repurposing Vorinostat for the Treatment of Disorders Affecting Brain"],"prefix":"10.1007","volume":"23","author":[{"given":"K. V.","family":"Athira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashant","family":"Sadanandan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8223-6508","authenticated-orcid":false,"given":"Sumana","family":"Chakravarty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,4]]},"reference":[{"issue":"1","key":"8660_CR1","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.coph.2007.12.002","volume":"8","author":"T Abel","year":"2008","unstructured":"Abel, T., & Zukin, R. S. (2008). Epigenetic targets of HDAC inhibition in neurodegenerative and psychiatric disorders. Current Opinion in Pharmacology, 8(1), 57\u201364","journal-title":"Current Opinion in Pharmacology"},{"issue":"6","key":"8660_CR2","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/j.neuron.2004.05.021","volume":"42","author":"JM Alarc\u00f3n","year":"2004","unstructured":"Alarc\u00f3n, J. M., Malleret, G., Touzani, K., Vronskaya, S., Ishii, S., Kandel, E. R., & Barco, A. (2004). Chromatin acetylation, memory, and LTP are impaired in CBP+\/\u2212 mice: a model for the cognitive deficit in Rubinstein-Taybi syndrome and its amelioration. Neuron, 42(6), 947\u2013959","journal-title":"Neuron"},{"key":"8660_CR3","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.neurobiolaging.2016.03.001","volume":"42","author":"S Almeida","year":"2016","unstructured":"Almeida, S., Gao, F., Coppola, G., & Gao, F.-B. (2016). Suberoylanilide hydroxamic acid increases progranulin production in iPSC-derived cortical neurons of frontotemporal dementia patients. Neurobiology of Aging, 42, 35\u201340","journal-title":"Neurobiology of Aging"},{"issue":"3","key":"8660_CR4","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.euroneuro.2014.12.007","volume":"25","author":"C Alquezar","year":"2015","unstructured":"Alquezar, C., Esteras, N., de la Encarnaci\u00f3n, A., Moreno, F., de Munain, A. L., & Mart\u00edn-Requero, \u00c1. (2015). Increasing progranulin levels and blockade of the ERK1\/2 pathway: Upstream and downstream strategies for the treatment of progranulin deficient frontotemporal dementia. European Neuropsychopharmacology, 25(3), 386\u2013403","journal-title":"European Neuropsychopharmacology"},{"issue":"3","key":"8660_CR5","doi-asserted-by":"publisher","first-page":"168","DOI":"10.2174\/1570159X17666191001142934","volume":"18","author":"KV Athira","year":"2020","unstructured":"Athira, K. V., Bandopadhyay, S., Samudrala, P. K., Naidu, V., Lahkar, M., & Chakravarty, S. (2020). An overview of the heterogeneity of major depressive disorder: Current knowledge and future prospective. Current Neuropharmacology, 18(3), 168\u2013187","journal-title":"Current Neuropharmacology"},{"key":"8660_CR6","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.bbr.2018.02.009","volume":"344","author":"K Athira","year":"2018","unstructured":"Athira, K., Madhana, R. M., Lahkar, M., Sinha, S., & Naidu, V. (2018). Antidepressant activity of vorinostat is associated with amelioration of oxidative stress and inflammation in a corticosterone-induced chronic stress model in mice. Behavioural Brain Research, 344, 73\u201384","journal-title":"Behavioural Brain Research"},{"key":"8660_CR7","doi-asserted-by":"publisher","first-page":"105083","DOI":"10.1016\/j.psyneuen.2020.105083","volume":"124","author":"K Athira","year":"2021","unstructured":"Athira, K., Wahul, A. B., Soren, K., Das, T., Dey, S., Samudrala, P. K., Kumar, A., Lahkar, M., & Chakravarty, S. (2021). Differential modulation of GR signaling and HDACs in the development of resilient\/vulnerable phenotype and antidepressant-like response of vorinostat. Psychoneuroendocrinology, 124, 105083","journal-title":"Psychoneuroendocrinology"},{"issue":"1","key":"8660_CR8","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/1756-6606-7-37","volume":"7","author":"VSR Atluri","year":"2014","unstructured":"Atluri, V. S. R., Pilakka-Kanthikeel, S., Samikkannu, T., Sagar, V., Kurapati, K. R. V., Saxena, S. K., Yndart, A., Raymond, A., Ding, H., & Hernandez, O. (2014). Vorinostat positively regulates synaptic plasticity genes expression and spine density in HIV infected neurons: Role of nicotine in progression of HIV-associated neurocognitive disorder. Molecular Brain, 7(1), 37","journal-title":"Molecular Brain"},{"issue":"9","key":"8660_CR9","doi-asserted-by":"publisher","first-page":"3572","DOI":"10.1172\/JCI79942","volume":"125","author":"E Benito","year":"2015","unstructured":"Benito, E., Urbanke, H., Ramachandran, B., Barth, J., Halder, R., Awasthi, A., Jain, G., Capece, V., Burkhardt, S., & Navarro-Sala, M. (2015). HDAC inhibitor\u2013dependent transcriptome and memory reinstatement in cognitive decline models. The Journal of Clinical Investigation, 125(9), 3572\u20133584","journal-title":"The Journal of Clinical Investigation"},{"issue":"12","key":"8660_CR10","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1016\/j.bbamcr.2006.07.010","volume":"1763","author":"J Berger","year":"2006","unstructured":"Berger, J., & G\u00e4rtner, J. (2006). X-linked adrenoleukodystrophy: Clinical, biochemical and pathogenetic aspects. Biochimica et Biophysica Acta B, 1763(12), 1721\u20131732","journal-title":"Biochimica et Biophysica Acta B"},{"issue":"5762","key":"8660_CR11","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1126\/science.1120972","volume":"311","author":"O Berton","year":"2006","unstructured":"Berton, O., McClung, C. A., DiLeone, R. J., Krishnan, V., Renthal, W., Russo, S. J., Graham, D., Tsankova, N. M., Bolanos, C. A., & Rios, M. (2006). Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress. Science, 311(5762), 864\u2013868","journal-title":"Science"},{"issue":"1","key":"8660_CR12","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/BF02686117","volume":"31","author":"RS Broide","year":"2007","unstructured":"Broide, R. S., Redwine, J. M., Aftahi, N., Young, W., Bloom, F. E., & Winrow, C. J. (2007). Distribution of histone deacetylases 1\u201311 in the rat brain. Journal of Molecular Neuroscience, 31(1), 47\u201358","journal-title":"Journal of Molecular Neuroscience"},{"issue":"2","key":"8660_CR13","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.canlet.2009.02.028","volume":"280","author":"M Buchwald","year":"2009","unstructured":"Buchwald, M., Kr\u00e4mer, O. H., & Heinzel, T. (2009). HDACi\u2013targets beyond chromatin. Cancer Letters, 280(2), 160\u2013167","journal-title":"Cancer Letters"},{"issue":"18","key":"8660_CR14","doi-asserted-by":"publisher","first-page":"16101","DOI":"10.1074\/jbc.M110.193433","volume":"286","author":"B Cenik","year":"2011","unstructured":"Cenik, B., Sephton, C. F., Dewey, C. M., Xian, X., Wei, S., Yu, K., Niu, W., Coppola, G., Coughlin, S. E., & Lee, S. E. (2011). Suberoylanilide hydroxamic acid (vorinostat) up-regulates progranulin transcription rational therapeutic approach to frontotemporal dementia. Journal of Biological Chemistry, 286(18), 16101\u201316108","journal-title":"Journal of Biological Chemistry"},{"key":"8660_CR15","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/B978-0-12-417114-5.00025-5","volume":"2","author":"S Chakravarty","year":"2014","unstructured":"Chakravarty, S., Bhat, U. A., Reddy, R. G., Gupta, P., & Kumar, A. (2014a). Histone deacetylase inhibitors and psychiatric disorders. Epigenetics in Psychiatry, 2, 515\u2013544","journal-title":"Epigenetics in Psychiatry"},{"key":"8660_CR16","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/B978-0-12-801311-3.00004-4","volume":"115","author":"S Chakravarty","year":"2014","unstructured":"Chakravarty, S., Pathak, S. S., Maitra, S., Khandelwal, N., Chandra, K. B., & Kumar, A. (2014b). Epigenetic regulatory mechanisms in stress-induced behavior. International Review of Neurobiology., 115, 117\u2013154","journal-title":"International Review of Neurobiology."},{"issue":"4","key":"8660_CR17","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.nano.2013.09.008","volume":"10","author":"P Chandran","year":"2014","unstructured":"Chandran, P., Kavalakatt, A., Malarvizhi, G. L., Vasanthakumari, D. R. V. N., Retnakumari, A. P., Sidharthan, N., Pavithran, K., Nair, S., & Koyakutty, M. (2014). Epigenetics targeted protein-vorinostat nanomedicine inducing apoptosis in heterogeneous population of primary acute myeloid leukemia cells including refractory and relapsed cases. Nanomedicine: Nanotechnology, Biology and Medicine, 10(4), 721\u2013732","journal-title":"Nanomedicine: Nanotechnology, Biology and Medicine"},{"issue":"2","key":"8660_CR18","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1111\/j.1476-5381.2011.01575.x","volume":"165","author":"S Chen","year":"2012","unstructured":"Chen, S., Wu, H., Ossola, B., Schendzielorz, N., Wilson, B. C., Chu, C.-H., Chen, S., Wang, Q., Zhang, D., & Qian, L. (2012). Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, protects dopaminergic neurons from neurotoxin-induced damage. British Journal of Pharmacology, 165(2), 494\u2013505","journal-title":"British Journal of Pharmacology"},{"issue":"5942","key":"8660_CR19","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1126\/science.1175371","volume":"325","author":"C Choudhary","year":"2009","unstructured":"Choudhary, C., Kumar, C., Gnad, F., Nielsen, M. L., Rehman, M., Walther, T. C., Olsen, J. V., & Mann, M. (2009). Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science, 325(5942), 834\u2013840","journal-title":"Science"},{"issue":"37","key":"8660_CR20","doi-asserted-by":"publisher","first-page":"11451","DOI":"10.1523\/JNEUROSCI.1758-09.2009","volume":"29","author":"HE Covington","year":"2009","unstructured":"Covington, H. E., Maze, I., LaPlant, Q. C., Vialou, V. F., Ohnishi, Y. N., Berton, O., Fass, D. M., Renthal, W., Rush, A. J., & Wu, E. Y. (2009). Antidepressant actions of histone deacetylase inhibitors. Journal of Neuroscience, 29(37), 11451\u201311460","journal-title":"Journal of Neuroscience"},{"issue":"1","key":"8660_CR21","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s13148-015-0142-9","volume":"7","author":"M Cuadrado-Tejedor","year":"2015","unstructured":"Cuadrado-Tejedor, M., Garcia-Barroso, C., Sanzhez-Arias, J., Mederos, S., Rabal, O., Ugarte, A., Franco, R., Pascual-Lucas, M., Segura, V., & Perea, G. (2015). Concomitant histone deacetylase and phosphodiesterase 5 inhibition synergistically prevents the disruption in synaptic plasticity and it reverses cognitive impairment in a mouse model of Alzheimer\u2019s disease. Clinical Epigenetics, 7(1), 108","journal-title":"Clinical Epigenetics"},{"issue":"3","key":"8660_CR22","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1042\/bj20021321","volume":"370","author":"AJ De Ruijter","year":"2003","unstructured":"De Ruijter, A. J., Van Gennip, A. H., Caron, H. N., Stephan, K., & Van Kuilenburg, A. B. (2003). Histone deacetylases (HDACs): Characterization of the classical HDAC family. Biochemical Journal, 370(3), 737\u2013749","journal-title":"Biochemical Journal"},{"issue":"2","key":"8660_CR23","doi-asserted-by":"publisher","first-page":"145","DOI":"10.2174\/1574892810666150317144511","volume":"10","author":"C De Souza","year":"2015","unstructured":"De Souza, C. (2015). P Chatterji B: HDAC inhibitors as novel anti-cancer therapeutics. Recent Patents on Anti-cancer Drug Discovery, 10(2), 145\u2013162","journal-title":"Recent Patents on Anti-cancer Drug Discovery"},{"key":"8660_CR24","doi-asserted-by":"publisher","first-page":"100040","DOI":"10.1016\/j.medidd.2020.100040","volume":"6","author":"C De Souza","year":"2020","unstructured":"De Souza, C., Lindstrom, A. R., Ma, Z., & Chatterji, B. P. (2020). Nanomaterials as potential transporters of HDAC inhibitors. Medicine in Drug Discovery, 6, 100040","journal-title":"Medicine in Drug Discovery"},{"issue":"12","key":"8660_CR25","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1016\/j.chembiol.2013.09.020","volume":"20","author":"X-J Di","year":"2013","unstructured":"Di, X.-J., Han, D.-Y., Wang, Y.-J., Chance, M. R., & Mu, T.-W. (2013). SAHA enhances proteostasis of epilepsy-associated \u03b11 (A322D) \u03b22\u03b32 GABAA receptors. Chemistry & Biology, 20(12), 1456\u20131468","journal-title":"Chemistry & Biology"},{"issue":"1","key":"8660_CR26","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/acn3.147","volume":"2","author":"A Didonna","year":"2015","unstructured":"Didonna, A., & Opal, P. (2015). The promise and perils of HDAC inhibitors in neurodegeneration. Annals of Clinical and Translational Neurology, 2(1), 79\u2013101","journal-title":"Annals of Clinical and Translational Neurology"},{"issue":"10","key":"8660_CR27","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1158\/1541-7786.MCR-07-0324","volume":"5","author":"M Dokmanovic","year":"2007","unstructured":"Dokmanovic, M., Clarke, C., & Marks, P. A. (2007). Histone deacetylase inhibitors: Overview and perspectives. Molecular Cancer Research, 5(10), 981\u2013989","journal-title":"Molecular Cancer Research"},{"key":"8660_CR28","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1146\/annurev.pharmtox.45.120403.095825","volume":"45","author":"DC Drummond","year":"2005","unstructured":"Drummond, D. C., Noble, C. O., Kirpotin, D. B., Guo, Z., Scott, G. K., & Benz, C. C. (2005). Clinical development of histone deacetylase inhibitors as anticancer agents. Annual Review of Pharmacology and Toxicology, 45, 495\u2013528","journal-title":"Annual Review of Pharmacology and Toxicology"},{"key":"8660_CR29","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3389\/fnmol.2018.00089","volume":"11","author":"N Durisic","year":"2018","unstructured":"Durisic, N., Keramidas, A., Dixon, C. L., & Lynch, J. W. (2018). SAHA (vorinostat) corrects inhibitory synaptic deficits caused by missense epilepsy mutations to the GABAA receptor \u03b32 subunit. Frontiers in Molecular Neuroscience, 11, 89","journal-title":"Frontiers in Molecular Neuroscience"},{"issue":"7","key":"8660_CR30","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.3390\/ijms18071414","volume":"18","author":"T Eckschlager","year":"2017","unstructured":"Eckschlager, T., Plch, J., Stiborova, M., & Hrabeta, J. (2017). Histone deacetylase inhibitors as anticancer drugs. International Journal of Molecular Sciences, 18(7), 1414","journal-title":"International Journal of Molecular Sciences"},{"issue":"4","key":"8660_CR31","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1111\/j.1471-4159.2005.03098.x","volume":"93","author":"IY Ey\u00fcpoglu","year":"2005","unstructured":"Ey\u00fcpoglu, I. Y., Hahnen, E., Buslei, R., Siebzehnr\u00fcbl, F. A., Savaskan, N. E., L\u00fcders, M., Tr\u00e4nkle, C., Wick, W., Weller, M., & Fahlbusch, R. (2005). Suberoylanilide hydroxamic acid (SAHA) has potent anti-glioma properties in vitro, ex vivo and in vivo. Journal of Neurochemistry, 93(4), 992\u2013999","journal-title":"Journal of Neurochemistry"},{"issue":"6","key":"8660_CR32","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1124\/mol.106.027912","volume":"70","author":"G Faraco","year":"2006","unstructured":"Faraco, G., Pancani, T., Formentini, L., Mascagni, P., Fossati, G., Leoni, F., Moroni, F., & Chiarugi, A. (2006). Pharmacological inhibition of histone deacetylases by suberoylanilide hydroxamic acid specifically alters gene expression and reduces ischemic injury in the mouse brain. Molecular Pharmacology, 70(6), 1876\u20131884","journal-title":"Molecular Pharmacology"},{"issue":"5","key":"8660_CR33","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1080\/13543776.2018.1459568","volume":"28","author":"M Faria Freitas","year":"2018","unstructured":"Faria Freitas, M., Cuendet, M., & Bertrand, P. (2018). HDAC inhibitors: a 2013\u20132017 patent survey. Expert Opinion on Therapeutic Patents, 28(5), 365\u2013381","journal-title":"Expert Opinion on Therapeutic Patents"},{"issue":"6749","key":"8660_CR34","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1038\/43710","volume":"401","author":"MS Finnin","year":"1999","unstructured":"Finnin, M. S., Donigian, J. R., Cohen, A., Richon, V. M., Rifkind, R. A., Marks, P. A., Breslow, R., & Pavletich, N. P. (1999). Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature, 401(6749), 188\u2013193","journal-title":"Nature"},{"issue":"5","key":"8660_CR35","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.jpsychires.2012.01.026","volume":"46","author":"Y Fujita","year":"2012","unstructured":"Fujita, Y., Morinobu, S., Takei, S., Fuchikami, M., Matsumoto, T., Yamamoto, S., & Yamawaki, S. (2012). Vorinostat, a histone deacetylase inhibitor, facilitates fear extinction and enhances expression of the hippocampal NR2B-containing NMDA receptor gene. Journal of Psychiatric Research, 46(5), 635\u2013643","journal-title":"Journal of Psychiatric Research"},{"issue":"12","key":"8660_CR36","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1200\/JCO.2008.19.0694","volume":"27","author":"E Galanis","year":"2009","unstructured":"Galanis, E., Jaeckle, K. A., Maurer, M. J., Reid, J. M., Ames, M. M., Hardwick, J. S., Reilly, J. F., Loboda, A., Nebozhyn, M., & Fantin, V. R. (2009). Phase II trial of vorinostat in recurrent glioblastoma multiforme: A north central cancer treatment group study. Journal of Clinical Oncology, 27(12), 2052","journal-title":"Journal of Clinical Oncology"},{"key":"8660_CR37","doi-asserted-by":"crossref","unstructured":"Gangisetty, O. & Murugan, S. (2016). Epigenetic modifications in neurological diseases: natural products as epigenetic modulators a treatment strategy. In The benefits of natural products for neurodegenerative diseases. (pp. 1\u201325). Springer.","DOI":"10.1007\/978-3-319-28383-8_1"},{"issue":"28","key":"8660_CR38","doi-asserted-by":"publisher","first-page":"25748","DOI":"10.1074\/jbc.M111871200","volume":"277","author":"L Gao","year":"2002","unstructured":"Gao, L., Cueto, M. A., Asselbergs, F., & Atadja, P. (2002). Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family. Journal of Biological Chemistry, 277(28), 25748\u201325755","journal-title":"Journal of Biological Chemistry"},{"key":"8660_CR39","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.expneurol.2012.12.006","volume":"241","author":"Z Ge","year":"2013","unstructured":"Ge, Z., Da, Y., Xue, Z., Zhang, K., Zhuang, H., Peng, M., Li, Y., Li, W., Simard, A., & Hao, J. (2013). Vorinostat, a histone deacetylase inhibitor, suppresses dendritic cell function and ameliorates experimental autoimmune encephalomyelitis. Experimental Neurology, 241, 56\u201366","journal-title":"Experimental Neurology"},{"key":"8660_CR40","volume-title":"Method of treating a CNS disorder using a water-soluble histone deacetylase inhibitor","author":"SS Gill","year":"2019","unstructured":"Gill, S. S. (2019). Method of treating a CNS disorder using a water-soluble histone deacetylase inhibitor. Google Patents."},{"issue":"3","key":"8660_CR41","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nm.3090","volume":"19","author":"SA Golden","year":"2013","unstructured":"Golden, S. A., Christoffel, D. J., Heshmati, M., Hodes, G. E., Magida, J., Davis, K., Cahill, M. E., Dias, C., Ribeiro, E., & Ables, J. L. (2013). Epigenetic regulation of RAC1 induces synaptic remodeling in stress disorders and depression. Nature Medicine, 19(3), 337","journal-title":"Nature Medicine"},{"issue":"2","key":"8660_CR42","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1124\/mol.109.061333","volume":"77","author":"DR Grayson","year":"2010","unstructured":"Grayson, D. R., Kundakovic, M., & Sharma, R. P. (2010). Is there a future for histone deacetylase inhibitors in the pharmacotherapy of psychiatric disorders? Molecular Pharmacology, 77(2), 126\u2013135","journal-title":"Molecular Pharmacology"},{"issue":"4","key":"8660_CR43","doi-asserted-by":"publisher","first-page":"505","DOI":"10.4155\/fmc.12.3","volume":"4","author":"BE Gryder","year":"2012","unstructured":"Gryder, B. E., Sodji, Q. H., & Oyelere, A. K. (2012). Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed. Future Medicinal Chemistry, 4(4), 505\u2013524","journal-title":"Future Medicinal Chemistry"},{"issue":"7243","key":"8660_CR44","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/nature07925","volume":"459","author":"J-S Guan","year":"2009","unstructured":"Guan, J.-S., Haggarty, S. J., Giacometti, E., Dannenberg, J.-H., Joseph, N., Gao, J., Nieland, T. J., Zhou, Y., Wang, X., & Mazitschek, R. (2009). HDAC2 negatively regulates memory formation and synaptic plasticity. Nature, 459(7243), 55","journal-title":"Nature"},{"issue":"1","key":"8660_CR45","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/nrg2485","volume":"10","author":"M Haberland","year":"2009","unstructured":"Haberland, M., Montgomery, R. L., & Olson, E. N. (2009). The many roles of histone deacetylases in development and physiology: Implications for disease and therapy. Nature Reviews Genetics, 10(1), 32","journal-title":"Nature Reviews Genetics"},{"issue":"1","key":"8660_CR46","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/j.1471-4159.2006.03868.x","volume":"98","author":"E Hahnen","year":"2006","unstructured":"Hahnen, E., Ey\u00fcpoglu, I. Y., Brichta, L., Haastert, K., Tr\u00e4nkle, C., Siebzehnr\u00fcbl, F. A., Riessland, M., H\u00f6lker, I., Claus, P., & Romst\u00f6ck, J. (2006). In vitro and ex vivo evaluation of second-generation histone deacetylase inhibitors for the treatment of spinal muscular atrophy. Journal of Neurochemistry, 98(1), 193\u2013202","journal-title":"Journal of Neurochemistry"},{"issue":"7","key":"8660_CR47","doi-asserted-by":"publisher","first-page":"e69964","DOI":"10.1371\/journal.pone.0069964","volume":"8","author":"JE Hanson","year":"2013","unstructured":"Hanson, J. E., La, H., Plise, E., Chen, Y.-H., Ding, X., Hanania, T., Sabath, E. V., Alexandrov, V., Brunner, D., & Leahy, E. (2013a). SAHA enhances synaptic function and plasticity in vitro but has limited brain availability in vivo and does not impact cognition. PLoS ONE, 8(7), e69964","journal-title":"PLoS ONE"},{"issue":"7","key":"8660_CR48","doi-asserted-by":"publisher","first-page":"e69968","DOI":"10.1371\/journal.pone.0069964","volume":"8","author":"JE Hanson","year":"2013","unstructured":"Hanson, J. E., La, H., Plise, E., Chen, Y.-H., Ding, X., Hanania, T., Sabath, E. V., Alexandrov, V., Brunner, D., & Leahy, E. (2013b). SAHA enhances synaptic function and plasticity in vitro but has limited brain availability in vivo and does not impact cognition. PLoS ONE, 8(7), e69968","journal-title":"PLoS ONE"},{"issue":"2","key":"8660_CR49","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1093\/hmg\/ddn357","volume":"18","author":"J Hauke","year":"2009","unstructured":"Hauke, J., Riessland, M., Lunke, S., Ey\u00fcpoglu, I. Y., Bl\u00fcmcke, I., El-Osta, A., Wirth, B., & Hahnen, E. (2009). Survival motor neuron gene 2 silencing by DNA methylation correlates with spinal muscular atrophy disease severity and can be bypassed by histone deacetylase inhibition. Human Molecular Genetics, 18(2), 304\u2013317","journal-title":"Human Molecular Genetics"},{"issue":"4","key":"8660_CR50","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1073\/pnas.0437870100","volume":"100","author":"E Hockly","year":"2003","unstructured":"Hockly, E., Richon, V. M., Woodman, B., Smith, D. L., Zhou, X., Rosa, E., Sathasivam, K., Ghazi-Noori, S., Mahal, A., & Lowden, P. A. (2003). Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington\u2019s disease. Proceedings of the National Academy of Sciences, 100(4), 2041\u20132046","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"2","key":"8660_CR51","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.bbmt.2018.09.015","volume":"25","author":"F Hoodin","year":"2019","unstructured":"Hoodin, F., LaLonde, L., Errickson, J., Votruba, K., Kentor, R., Gatza, E., Reddy, P., & Choi, S. W. (2019). Cognitive function and quality of life in vorinostat-treated patients after matched unrelated donor myeloablative conditioning hematopoietic cell transplantation. Biology of Blood and Marrow Transplantation, 25(2), 343\u2013353","journal-title":"Biology of Blood and Marrow Transplantation"},{"issue":"8","key":"8660_CR52","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1038\/nm.2828","volume":"18","author":"M Jakovcevski","year":"2012","unstructured":"Jakovcevski, M., & Akbarian, S. (2012). Epigenetic mechanisms in neurological disease. Nature Medicine, 18(8), 1194","journal-title":"Nature Medicine"},{"key":"8660_CR53","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.2147\/IJN.S76517","volume":"10","author":"RD Jayant","year":"2015","unstructured":"Jayant, R. D., Atluri, V. S., Agudelo, M., Sagar, V., Kaushik, A., & Nair, M. (2015). Sustained-release nanoART formulation for the treatment of neuroAIDS. International Journal of Nanomedicine, 10, 1077","journal-title":"International Journal of Nanomedicine"},{"issue":"6","key":"8660_CR54","doi-asserted-by":"publisher","first-page":"815","DOI":"10.2174\/1570159X14666161213143907","volume":"15","author":"P Jhelum","year":"2017","unstructured":"Jhelum, P., Karisetty, B., Kumar, A., & Chakravarty, S. (2017). Implications of epigenetic mechanisms and their targets in cerebral ischemia models. Current Neuropharmacology, 15(6), 815\u2013830","journal-title":"Current Neuropharmacology"},{"issue":"2","key":"8660_CR55","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/npp.2013.207","volume":"39","author":"J Jochems","year":"2014","unstructured":"Jochems, J., Boulden, J., Lee, B. G., Blendy, J. A., Jarpe, M., Mazitschek, R., Van Duzer, J. H., Jones, S., & Berton, O. (2014). Antidepressant-like properties of novel HDAC6-selective inhibitors with improved brain bioavailability. Neuropsychopharmacology, 39(2), 389","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"8660_CR56","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S1535-6108(03)00165-X","volume":"4","author":"RW Johnstone","year":"2003","unstructured":"Johnstone, R. W., & Licht, J. D. (2003). Histone deacetylase inhibitors in cancer therapy: Is transcription the primary target? Cancer Cell, 4(1), 13\u201318","journal-title":"Cancer Cell"},{"issue":"10","key":"8660_CR57","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1038\/nrd2681","volume":"7","author":"AG Kazantsev","year":"2008","unstructured":"Kazantsev, A. G., & Thompson, L. M. (2008). Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nature Reviews Drug Discovery, 7(10), 854\u2013868","journal-title":"Nature Reviews Drug Discovery"},{"issue":"17","key":"8660_CR58","doi-asserted-by":"publisher","first-page":"3923","DOI":"10.1200\/JCO.2005.14.167","volume":"23","author":"WK Kelly","year":"2005","unstructured":"Kelly, W. K., O\u2019Connor, O. A., Krug, M. L., Chiao, J. H., Heaney, M., Curley, T., MacGregore-Cortelli, B., Tong, W., Secrist, J. P., & Schwartz, L. (2005). Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. Journal of Clinical Oncology, 23(17), 3923","journal-title":"Journal of Clinical Oncology"},{"issue":"10","key":"8660_CR59","first-page":"3578","volume":"9","author":"WK Kelly","year":"2003","unstructured":"Kelly, W. K., Richon, V. M., O\u2019Connor, O., Curley, T., MacGregor-Curtelli, B., Tong, W., Klang, M., Schwartz, L., Richardson, S., & Rosa, E. (2003). Phase I clinical trial of histone deacetylase inhibitor: Suberoylanilide hydroxamic acid administered intravenously. Clinical Cancer Research, 9(10), 3578\u20133588","journal-title":"Clinical Cancer Research"},{"key":"8660_CR60","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.brainres.2010.07.041","volume":"1354","author":"SK Kidd","year":"2010","unstructured":"Kidd, S. K., & Schneider, J. S. (2010). Protection of dopaminergic cells from MPP+-mediated toxicity by histone deacetylase inhibition. Brain Research, 1354, 172\u2013178","journal-title":"Brain Research"},{"issue":"4","key":"8660_CR61","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1038\/npp.2009.197","volume":"35","author":"M Kilgore","year":"2010","unstructured":"Kilgore, M., Miller, C. A., Fass, D. M., Hennig, K. M., Haggarty, S. J., Sweatt, J. D., & Rumbaugh, G. (2010). Inhibitors of class 1 histone deacetylases reverse contextual memory deficits in a mouse model of Alzheimer\u2019s disease. Neuropsychopharmacology, 35(4), 870\u2013880","journal-title":"Neuropsychopharmacology"},{"issue":"20","key":"8660_CR62","doi-asserted-by":"publisher","first-page":"3012","DOI":"10.1093\/hmg\/ddl243","volume":"15","author":"E Kontopoulos","year":"2006","unstructured":"Kontopoulos, E., Parvin, J. D., & Feany, M. B. (2006). \u03b1-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity. Human Molecular Genetics, 15(20), 3012\u20133023","journal-title":"Human Molecular Genetics"},{"key":"8660_CR63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2012\/184154","volume":"2012","author":"A Kretsovali","year":"2012","unstructured":"Kretsovali, A., Hadjimichael, C., & Charmpilas, N. (2012). Histone deacetylase inhibitors in cell pluripotency, differentiation, and reprogramming. Stem Cells International, 2012, 1\u201310","journal-title":"Stem Cells International"},{"key":"8660_CR64","first-page":"1","volume":"1","author":"R Kuta","year":"2020","unstructured":"Kuta, R., Larochelle, N., Fernandez, M., Pal, A., Minotti, S., Tibshirani, M., Louis, K. S., Gentil, B. J., Nalbantoglu, J. N., & Hermann, A. (2020). Depending on the stress, histone deacetylase inhibitors act as heat shock protein co-inducers in motor neurons and potentiate arimoclomol, exerting neuroprotection through multiple mechanisms in ALS models. Cell Stress and Chaperones, 1, 1\u201319","journal-title":"Cell Stress and Chaperones"},{"issue":"17","key":"8660_CR65","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1021\/acschemneuro.0c00315","volume":"11","author":"A Kv","year":"2020","unstructured":"Kv, A., Madhana, R. M., Bais, A. K., Singh, V. B., Malik, A., Sinha, S., Lahkar, M., Kumar, P., & Samudrala, P. K. (2020). Cognitive improvement by vorinostat through modulation of endoplasmic reticulum stress in a corticosterone-induced chronic stress model in mice. ACS Chemical Neuroscience, 11(17), 2649\u20132657","journal-title":"ACS Chemical Neuroscience"},{"issue":"15","key":"8660_CR66","doi-asserted-by":"publisher","first-page":"3289","DOI":"10.1016\/j.bmcl.2017.06.027","volume":"27","author":"J-I Lai","year":"2017","unstructured":"Lai, J.-I., Leman, L. J., Ku, S., Vickers, C. J., Olsen, C. A., Montero, A., Ghadiri, M. R., & Gottesfeld, J. M. (2017). Cyclic tetrapeptide HDAC inhibitors as potential therapeutics for spinal muscular atrophy: Screening with iPSC-derived neuronal cells. Bioorganic & Medicinal Chemistry Letters, 27(15), 3289\u20133293","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"issue":"2","key":"8660_CR67","first-page":"615","volume":"35","author":"P Lee","year":"2015","unstructured":"Lee, P., Murphy, B., Miller, R., Menon, V., Banik, N. L., Giglio, P., Lindhorst, S. M., & Varma, A. K. (2015). Mechanisms and clinical significance of histone deacetylase inhibitors: epigenetic glioblastoma therapy. Anticancer Research, 35(2), 615\u2013625","journal-title":"Anticancer Research"},{"key":"8660_CR68","doi-asserted-by":"publisher","first-page":"893","DOI":"10.3389\/fneur.2019.00893","volume":"10","author":"S Li","year":"2019","unstructured":"Li, S., Lu, X., Shao, Q., Chen, Z., Huang, Q., Jiao, Z., Huang, X., Yue, M., Peng, J., & Zhou, X. (2019). Early histone deacetylase inhibition mitigates ischemia\/reperfusion brain injury by reducing microglia activation and modulating their phenotype. Frontiers in Neurology, 10, 893","journal-title":"Frontiers in Neurology"},{"issue":"19","key":"8660_CR69","doi-asserted-by":"publisher","first-page":"8071","DOI":"10.1073\/pnas.0702294104","volume":"104","author":"R Lindemann","year":"2007","unstructured":"Lindemann, R., Newbold, A., Whitecross, K., Cluse, L., Frew, A., Ellis, L., Williams, S., Wiegmans, A., Dear, A., & Scott, C. (2007). Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma. Proceedings of the National Academy of Sciences, 104(19), 8071\u20138076","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"34","key":"8660_CR70","doi-asserted-by":"publisher","first-page":"3940","DOI":"10.2174\/138161209789649349","volume":"15","author":"A Mai","year":"2009","unstructured":"Mai, A., Rotili, D., Valente, S., & Kazantsev, A. G. (2009). Histone deacetylase inhibitors and neurodegenerative disorders: Holding the promise. Current Pharmaceutical Design, 15(34), 3940\u20133957","journal-title":"Current Pharmaceutical Design"},{"issue":"10","key":"8660_CR71","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1634\/theoncologist.12-10-1247","volume":"12","author":"BS Mann","year":"2007","unstructured":"Mann, B. S., Johnson, J. R., Cohen, M. H., Justice, R., & Pazdur, R. (2007). FDA approval summary: Vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. The Oncologist, 12(10), 1247\u20131252","journal-title":"The Oncologist"},{"issue":"1","key":"8660_CR72","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/nbt1272","volume":"25","author":"PA Marks","year":"2007","unstructured":"Marks, P. A., & Breslow, R. (2007). Dimethyl sulfoxide to vorinostat: Development of this histone deacetylase inhibitor as an anticancer drug. Nature Biotechnology, 25(1), 84\u201390","journal-title":"Nature Biotechnology"},{"issue":"12","key":"8660_CR73","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1517\/13543784.14.12.1497","volume":"14","author":"PA Marks","year":"2005","unstructured":"Marks, P. A., & Dokmanovic, M. (2005). Histone deacetylase inhibitors: discovery and development as anticancer agents. Expert opinion on investigational drugs, 14(12), 1497\u20131511","journal-title":"Expert opinion on investigational drugs"},{"issue":"6","key":"8660_CR74","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1016\/j.bcp.2004.05.034","volume":"68","author":"F McLaughlin","year":"2004","unstructured":"McLaughlin, F., & La Thangue, N. B. (2004). Histone deacetylase inhibitors open new doors in cancer therapy. Biochemical Pharmacology, 68(6), 1139\u20131144","journal-title":"Biochemical Pharmacology"},{"issue":"1","key":"8660_CR75","doi-asserted-by":"publisher","first-page":"e85570","DOI":"10.1371\/journal.pone.0085570","volume":"9","author":"J Meng","year":"2014","unstructured":"Meng, J., Li, Y., Camarillo, C., Yao, Y., Zhang, Y., Xu, C., & Jiang, L. (2014). The anti-tumor histone deacetylase inhibitor SAHA and the natural flavonoid curcumin exhibit synergistic neuroprotection against amyloid-beta toxicity. PLoS ONE, 9(1), e85570","journal-title":"PLoS ONE"},{"key":"8660_CR76","doi-asserted-by":"publisher","first-page":"e6716","DOI":"10.7717\/peerj.6716","volume":"7","author":"J Meng","year":"2019","unstructured":"Meng, J., Li, Y., Zhang, M., Li, W., Zhou, L., Wang, Q., Lin, L., Jiang, L., & Zhu, W. (2019). A combination of curcumin, vorinostat and silibinin reverses A\u03b2-induced nerve cell toxicity via activation of AKT-MDM2-p53 pathway. PeerJ, 7, e6716","journal-title":"PeerJ"},{"key":"8660_CR77","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.neuropharm.2016.03.012","volume":"107","author":"EM Meylan","year":"2016","unstructured":"Meylan, E. M., Halfon, O., Magistretti, P. J., & Cardinaux, J.-R. (2016). The HDAC inhibitor SAHA improves depressive-like behavior of CRTC1-deficient mice: possible relevance for treatment-resistant depression. Neuropharmacology, 107, 111\u2013121","journal-title":"Neuropharmacology"},{"issue":"11","key":"8660_CR78","doi-asserted-by":"publisher","first-page":"e203","DOI":"10.1371\/journal.pone.0027746","volume":"6","author":"M Mielcarek","year":"2011","unstructured":"Mielcarek, M., Benn, C. L., Franklin, S. A., Smith, D. L., Woodman, B., Marks, P. A., & Bates, G. P. (2011). SAHA decreases HDAC 2 and 4 levels in vivo and improves molecular phenotypes in the R6\/2 mouse model of Huntington\u2019s disease. PLoS ONE, 6(11), e203","journal-title":"PLoS ONE"},{"issue":"2","key":"8660_CR79","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1073\/pnas.2536759100","volume":"101","author":"CS Mitsiades","year":"2004","unstructured":"Mitsiades, C. S., Mitsiades, N. S., McMullan, C. J., Poulaki, V., Shringarpure, R., Hideshima, T., Akiyama, M., Chauhan, D., Munshi, N., & Gu, X. (2004). Transcriptional signature of histone deacetylase inhibition in multiple myeloma: Biological and clinical implications. Proceedings of the National Academy of Sciences, 101(2), 540\u2013545","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"8660_CR80","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.ejps.2016.09.029","volume":"96","author":"EA Mohamed","year":"2017","unstructured":"Mohamed, E. A., Hashim, I. I. A., Yusif, R. M., Suddek, G. M., Shaaban, A. A. A., & Badria, F. A. E. (2017). Enhanced in vitro cytotoxicity and anti-tumor activity of vorinostat-loaded pluronic micelles with prolonged release and reduced hepatic and renal toxicities. European Journal of Pharmaceutical Sciences, 96, 232\u2013242","journal-title":"European Journal of Pharmaceutical Sciences"},{"issue":"10","key":"8660_CR81","doi-asserted-by":"publisher","first-page":"3787","DOI":"10.1002\/jps.23265","volume":"101","author":"EA Mohamed","year":"2012","unstructured":"Mohamed, E. A., Zhao, Y., Meshali, M. M., Remsberg, C. M., Borg, T. M., Foda, A. M. M., Takemoto, J. K., Sayre, C. L., Martinez, S. E., & Davies, N. M. (2012). Vorinostat with sustained exposure and high solubility in poly (ethylene glycol)-b-poly (dl-lactic acid) micelle nanocarriers: Characterization and effects on pharmacokinetics in rat serum and urine. Journal of Pharmaceutical Sciences, 101(10), 3787\u20133798","journal-title":"Journal of Pharmaceutical Sciences"},{"issue":"6","key":"8660_CR82","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.ijdevneu.2013.02.005","volume":"31","author":"MJ Morris","year":"2013","unstructured":"Morris, M. J., & Monteggia, L. M. (2013). Unique functional roles for class I and class II histone deacetylases in central nervous system development and function. International Journal of Developmental Neuroscience, 31(6), 370\u2013381","journal-title":"International Journal of Developmental Neuroscience"},{"issue":"2","key":"8660_CR83","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.canlet.2011.03.010","volume":"306","author":"S Mueller","year":"2011","unstructured":"Mueller, S., Yang, X., Sottero, T. L., Gragg, A., Prasad, G., Polley, M.-Y., Weiss, W. A., Matthay, K. K., Davidoff, A. M., & DuBois, S. G. (2011). Cooperation of the HDAC inhibitor vorinostat and radiation in metastatic neuroblastoma: Efficacy and underlying mechanisms. Cancer Letters, 306(2), 223\u2013229","journal-title":"Cancer Letters"},{"issue":"11","key":"8660_CR84","doi-asserted-by":"publisher","first-page":"4395","DOI":"10.1074\/jbc.M116.770578","volume":"292","author":"AB Munkacsi","year":"2017","unstructured":"Munkacsi, A. B., Hammond, N., Schneider, R. T., Senanayake, D. S., Higaki, K., Lagutin, K., Bloor, S. J., Ory, D. S., Maue, R. A., & Chen, F. W. (2017). Normalization of hepatic homeostasis in the Npc1nmf164 mouse model of Niemann-Pick type C disease treated with the histone deacetylase inhibitor vorinostat. Journal of Biological Chemistry, 292(11), 4395\u20134410","journal-title":"Journal of Biological Chemistry"},{"issue":"11","key":"8660_CR85","doi-asserted-by":"publisher","first-page":"3206","DOI":"10.1093\/brain\/awv250","volume":"138","author":"PL Musolino","year":"2015","unstructured":"Musolino, P. L., Gong, Y., Snyder, J. M., Jimenez, S., Lok, J., Lo, E. H., Moser, A. B., Grabowski, E. F., Frosch, M. P., & Eichler, F. S. (2015). Brain endothelial dysfunction in cerebral adrenoleukodystrophy. Brain, 138(11), 3206\u20133220","journal-title":"Brain"},{"issue":"2","key":"8660_CR86","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.neulet.2010.03.041","volume":"475","author":"T Nuutinen","year":"2010","unstructured":"Nuutinen, T., Suuronen, T., Kauppinen, A., & Salminen, A. (2010). Valproic acid stimulates clusterin expression in human astrocytes: Implications for Alzheimer\u2019s disease. Neuroscience Letters, 475(2), 64\u201368","journal-title":"Neuroscience Letters"},{"issue":"18 suppl","key":"8660_CR87","doi-asserted-by":"publisher","first-page":"7500","DOI":"10.1200\/jco.2006.24.18_suppl.7500","volume":"24","author":"E Olsen","year":"2006","unstructured":"Olsen, E., Kim, Y., Kuzel, T., Pacheco, T., Foss, F., Parker, S., Wang, J., Frankel, S., Lis, J., & Duvic, M. (2006). Vorinostat (suberoylanilide hydroxamic acid, SAHA) is clinically active in advanced cutaneous T-cell lymphoma (CTCL): Results of a phase IIb trial. Journal of Clinical Oncology, 24(18 suppl), 7500\u20137500","journal-title":"Journal of Clinical Oncology"},{"issue":"19","key":"8660_CR88","doi-asserted-by":"publisher","first-page":"6148","DOI":"10.1158\/1078-0432.CCR-09-1039","volume":"15","author":"D Palmieri","year":"2009","unstructured":"Palmieri, D., Lockman, P. R., Thomas, F. C., Hua, E., Herring, J., Hargrave, E., Johnson, M., Flores, N., Qian, Y., & Vega-Valle, E. (2009). Vorinostat inhibits brain metastatic colonization in a model of triple-negative breast cancer and induces DNA double-strand breaks. Clinical Cancer Research, 15(19), 6148\u20136157","journal-title":"Clinical Cancer Research"},{"issue":"1","key":"8660_CR89","first-page":"27","volume":"93","author":"P Peixoto","year":"2006","unstructured":"Peixoto, P., & Lansiaux, A. (2006). Histone-deacetylases inhibitors: from TSA to SAHA. Bulletin du Cancer, 93(1), 27\u201336","journal-title":"Bulletin du Cancer"},{"issue":"4","key":"8660_CR90","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1194\/jlr.M072140","volume":"58","author":"NH Pipalia","year":"2017","unstructured":"Pipalia, N. H., Subramanian, K., Mao, S., Ralph, H., Hutt, D. M., Scott, S. M., Balch, W. E., & Maxfield, F. R. (2017). Histone deacetylase inhibitors correct the cholesterol storage defect in most Niemann-Pick C1 mutant cells. Journal of Lipid Research, 58(4), 695\u2013708","journal-title":"Journal of Lipid Research"},{"issue":"7","key":"8660_CR91","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1517\/13543776.17.7.745","volume":"17","author":"S Price","year":"2007","unstructured":"Price, S., & Dyke, H. J. (2007). Histone deacetylase inhibitors: An analysis of recent patenting activity. Expert Opinion on Therapeutic Patents, 17(7), 745\u2013765","journal-title":"Expert Opinion on Therapeutic Patents"},{"issue":"7","key":"8660_CR92","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1074\/mcp.M114.045609","volume":"14","author":"N Rauniyar","year":"2015","unstructured":"Rauniyar, N., Subramanian, K., Lavall\u00e9e-Adam, M., Mart\u00ednez-Bartolom\u00e9, S., Balch, W. E., & Yates, J. R. (2015). Quantitative proteomics of human fibroblasts with I1061T mutation in Niemann-Pick C1 (NPC1) protein provides insights into the disease pathogenesis. Molecular & Cellular Proteomics, 14(7), 1734\u20131749","journal-title":"Molecular & Cellular Proteomics"},{"issue":"17","key":"8660_CR93","doi-asserted-by":"publisher","first-page":"17279","DOI":"10.1021\/acsomega.9b01950","volume":"4","author":"RG Reddy","year":"2019","unstructured":"Reddy, R. G., Surineni, G., Bhattacharya, D., Marvadi, S. K., Sagar, A., Kalle, A. M., Kumar, A., Kantevari, S., & Chakravarty, S. (2019). Crafting carbazole-based vorinostat and tubastatin-A-like histone deacetylase (HDAC) inhibitors with potent in vitro and in vivo neuroactive functions. ACS Omega, 4(17), 17279\u201317294","journal-title":"ACS Omega"},{"issue":"12","key":"8660_CR94","doi-asserted-by":"publisher","first-page":"5705","DOI":"10.1073\/pnas.93.12.5705","volume":"93","author":"V Richon","year":"1996","unstructured":"Richon, V., Webb, Y., Merger, R., Sheppard, T., Jursic, B., Ngo, L., Civoli, F., Breslow, R., Rifkind, R., & Marks, P. (1996). Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proceedings of the National Academy of Sciences, 93(12), 5705\u20135708","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"8","key":"8660_CR95","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1093\/hmg\/ddq023","volume":"19","author":"M Riessland","year":"2010","unstructured":"Riessland, M., Ackermann, B., F\u00f6rster, A., Jakubik, M., Hauke, J., Garbes, L., Fritzsche, I., Mende, Y., Blumcke, I., & Hahnen, E. (2010). SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy. Human Molecular Genetics, 19(8), 1492\u20131506","journal-title":"Human Molecular Genetics"},{"issue":"1","key":"8660_CR96","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1093\/jnci\/djq458","volume":"103","author":"AG Rooney","year":"2011","unstructured":"Rooney, A. G., Carson, A., & Grant, R. (2011). Depression in cerebral glioma patients: A systematic review of observational studies. Journal of the National Cancer Institute, 103(1), 61\u201376","journal-title":"Journal of the National Cancer Institute"},{"issue":"8","key":"8660_CR97","doi-asserted-by":"publisher","first-page":"e71323","DOI":"10.1371\/journal.pone.0071323","volume":"8","author":"FA Schroeder","year":"2013","unstructured":"Schroeder, F. A., Lewis, M. C., Fass, D. M., Wagner, F. F., Zhang, Y.-L., Hennig, K. M., Gale, J., Zhao, W.-N., Reis, S., & Barker, D. D. (2013). A selective HDAC 1\/2 inhibitor modulates chromatin and gene expression in brain and alters mouse behavior in two mood-related tests. PLoS ONE, 8(8), e71323","journal-title":"PLoS ONE"},{"issue":"7","key":"8660_CR98","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1021\/cn500021p","volume":"5","author":"YJ Seo","year":"2014","unstructured":"Seo, Y. J., Kang, Y., Muench, L., Reid, A., Caesar, S., Jean, L., Wagner, F., Holson, E., Haggarty, S. J., & Weiss, P. (2014). Image-guided synthesis reveals potent blood-brain barrier permeable histone deacetylase inhibitors. ACS Chemical Neuroscience, 5(7), 588\u2013596","journal-title":"ACS Chemical Neuroscience"},{"key":"8660_CR99","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1146\/annurev.biochem.76.052705.162114","volume":"76","author":"MD Shahbazian","year":"2007","unstructured":"Shahbazian, M. D., & Grunstein, M. (2007). Functions of site-specific histone acetylation and deacetylation. Annual Review of Biochemistry, 76, 75\u2013100","journal-title":"Annual Review of Biochemistry"},{"issue":"7","key":"8660_CR100","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/j.chembiol.2017.06.010","volume":"24","author":"A She","year":"2017","unstructured":"She, A., Kurtser, I., Reis, S. A., Hennig, K., Lai, J., Lang, A., Zhao, W.-N., Mazitschek, R., Dickerson, B. C., & Herz, J. (2017). Selectivity and kinetic requirements of HDAC inhibitors as progranulin enhancers for treating frontotemporal dementia. Cell Chemical Biology, 24(7), 892\u2013906","journal-title":"Cell Chemical Biology"},{"issue":"2","key":"8660_CR101","doi-asserted-by":"publisher","first-page":"W158","DOI":"10.2214\/AJR.14.12518","volume":"203","author":"H Shim","year":"2014","unstructured":"Shim, H., Wei, L., Holder, C. A., Guo, Y., Hu, X. P., Miller, A. H., & Olson, J. J. (2014). Use of high-resolution volumetric MR spectroscopic imaging in assessing treatment response of glioblastoma to an HDAC inhibitor. American Journal of Roentgenology, 203(2), W158\u2013W165","journal-title":"American Journal of Roentgenology"},{"issue":"2","key":"8660_CR102","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s12975-015-0421-y","volume":"7","author":"S Sukumari-Ramesh","year":"2016","unstructured":"Sukumari-Ramesh, S., Alleyne, C. H., & Dhandapani, K. M. (2016). The histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) confers acute neuroprotection after intracerebral hemorrhage in mice. Translational Stroke Research, 7(2), 141\u2013148","journal-title":"Translational Stroke Research"},{"key":"8660_CR103","doi-asserted-by":"publisher","first-page":"92","DOI":"10.3389\/fonc.2018.00092","volume":"8","author":"A Suraweera","year":"2018","unstructured":"Suraweera, A., O\u2019Byrne, K. J., & Richard, D. J. (2018). Combination therapy with histone deacetylase inhibitors (HDACi) for the treatment of cancer: achieving the full therapeutic potential of HDACi. Frontiers in Oncology, 8, 92","journal-title":"Frontiers in Oncology"},{"issue":"3","key":"8660_CR104","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1073\/pnas.72.3.1003","volume":"72","author":"M Tanaka","year":"1975","unstructured":"Tanaka, M., Levy, J., Terada, M., Breslow, R., Rifkind, R. A., & Marks, P. A. (1975). Induction of erythroid differentiation in murine virus infected eythroleukemia cells by highly polar compounds. Proceedings of the National Academy of Sciences, 72(3), 1003\u20131006","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"4","key":"8660_CR105","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/nn1659","volume":"9","author":"NM Tsankova","year":"2006","unstructured":"Tsankova, N. M., Berton, O., Renthal, W., Kumar, A., Neve, R. L., & Nestler, E. J. (2006). Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nature Neuroscience, 9(4), 519","journal-title":"Nature Neuroscience"},{"issue":"2","key":"8660_CR106","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.neuron.2010.12.023","volume":"69","author":"S Uchida","year":"2011","unstructured":"Uchida, S., Hara, K., Kobayashi, A., Otsuki, K., Yamagata, H., Hobara, T., Suzuki, T., Miyata, N., & Watanabe, Y. (2011). Epigenetic status of Gdnf in the ventral striatum determines susceptibility and adaptation to daily stressful events. Neuron, 69(2), 359\u2013372","journal-title":"Neuron"},{"issue":"3","key":"8660_CR107","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s11060-007-9337-z","volume":"83","author":"HC Ugur","year":"2007","unstructured":"Ugur, H. C., Ramakrishna, N., Bello, L., Menon, L. G., Kim, S.-K., Black, P. M., & Carroll, R. S. (2007). Continuous intracranial administration of suberoylanilide hydroxamic acid (SAHA) inhibits tumor growth in an orthotopic glioma model. Journal of Neuro-Oncology, 83(3), 267\u2013275","journal-title":"Journal of Neuro-Oncology"},{"issue":"8","key":"8660_CR108","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/ja.2011.35","volume":"64","author":"KM VanderMolen","year":"2011","unstructured":"VanderMolen, K. M., McCulloch, W., Pearce, C. J., & Oberlies, N. H. (2011). Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): A natural product recently approved for cutaneous T-cell lymphoma. The Journal of Antibiotics, 64(8), 525","journal-title":"The Journal of Antibiotics"},{"issue":"4","key":"8660_CR109","doi-asserted-by":"publisher","first-page":"583","DOI":"10.18433\/J3TS4V","volume":"17","author":"Y Wang","year":"2014","unstructured":"Wang, Y., Tu, S., Steffen, D., & Xiong, M. P. (2014). Iron complexation to histone deacetylase inhibitors SAHA and LAQ824 in PEGylated liposomes can considerably improve pharmacokinetics in rats. Journal of Pharmacy & Pharmaceutical Sciences, 17(4), 583","journal-title":"Journal of Pharmacy & Pharmaceutical Sciences"},{"issue":"24","key":"8660_CR110","doi-asserted-by":"publisher","first-page":"6482","DOI":"10.1016\/j.bmcl.2008.10.058","volume":"18","author":"PL Wash","year":"2008","unstructured":"Wash, P. L., Hoffman, T. Z., Wiley, B. M., Bonnefous, C., Smith, N. D., Sertic, M. S., Lawrence, C. M., Symons, K. T., Nguyen, P.-M., & Lustig, K. D. (2008). \u03b1-Mercaptoketone based histone deacetylase inhibitors. Bioorganic & Medicinal Chemistry Letters, 18(24), 6482\u20136485","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"issue":"9","key":"8660_CR111","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1002\/nbm.2776","volume":"25","author":"L Wei","year":"2012","unstructured":"Wei, L., Hong, S., Yoon, Y., Hwang, S. N., Park, J. C., Zhang, Z., Olson, J. J., Hu, X. P., & Shim, H. (2012). Early prediction of response to Vorinostat in an orthotopic rat glioma model. NMR in Biomedicine, 25(9), 1104\u20131111","journal-title":"NMR in Biomedicine"},{"key":"8660_CR112","doi-asserted-by":"publisher","first-page":"179","DOI":"10.5114\/fn.2018.78697","volume":"56","author":"J Xu","year":"2018","unstructured":"Xu, J., Shi, J., Zhang, J., & Zhang, Y. (2018). Vorinostat: a histone deacetylases (HDAC) inhibitor ameliorates traumatic brain injury by inducing iNOS\/Nrf2\/ARE pathway. Folia Neuropathologica, 56, 179\u2013186","journal-title":"Folia Neuropathologica"},{"issue":"3","key":"8660_CR113","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1073\/pnas.1221046110","volume":"110","author":"C Yang","year":"2013","unstructured":"Yang, C., Rahimpour, S., Lu, J., Pacak, K., Ikejiri, B., Brady, R. O., & Zhuang, Z. (2013). Histone deacetylase inhibitors increase glucocerebrosidase activity in Gaucher disease by modulation of molecular chaperones. Proceedings of the National Academy of Sciences, 110(3), 966\u2013971","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"3","key":"8660_CR114","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1158\/1078-0432.CCR-06-1261","volume":"13","author":"D Yin","year":"2007","unstructured":"Yin, D., Ong, J. M., Hu, J., Desmond, J. C., Kawamata, N., Konda, B. M., Black, K. L., & Koeffler, H. P. (2007). Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: Effects on gene expression and growth of glioma cells in vitro and in vivo. Clinical Cancer Research, 13(3), 1045\u20131052","journal-title":"Clinical Cancer Research"},{"issue":"3","key":"8660_CR115","doi-asserted-by":"publisher","first-page":"177","DOI":"10.2131\/jts.44.177","volume":"44","author":"Q Yu","year":"2019","unstructured":"Yu, Q., Feng, N., Hu, Y., Luo, F., Zhao, W., Zhao, W., Liu, Z., Li, M., Xu, L., & Wu, L. (2019). Suberoylanilide hydroxamic acid (SAHA) alleviates the learning and memory impairment in rat offspring caused by maternal sevoflurane exposure during late gestation. The Journal of Toxicological Sciences, 44(3), 177\u2013189","journal-title":"The Journal of Toxicological Sciences"},{"issue":"6","key":"8660_CR116","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1002\/med.21437","volume":"37","author":"C Zagni","year":"2017","unstructured":"Zagni, C., Floresta, G., Monciino, G., & Rescifina, A. (2017). The search for potent, small-molecule HDACIs in cancer treatment: A decade after vorinostat. Medicinal Research Reviews, 37(6), 1373\u20131428","journal-title":"Medicinal Research Reviews"},{"issue":"10","key":"8660_CR117","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1093\/jnen\/nly073","volume":"77","author":"M Ziemka-Nalecz","year":"2018","unstructured":"Ziemka-Nalecz, M., Jaworska, J., Sypecka, J., & Zalewska, T. (2018). Histone deacetylase inhibitors: A therapeutic key in neurological disorders? Journal of Neuropathology & Experimental Neurology, 77(10), 855\u2013870","journal-title":"Journal of Neuropathology & Experimental Neurology"},{"key":"8660_CR118","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1002\/acn3.51015","volume":"7","author":"B Zierfuss","year":"2020","unstructured":"Zierfuss, B., Weinhofer, I., K\u00fchl, J. S., K\u00f6hler, W., Bley, A., Zauner, K., Binder, J., Martinovi\u0107, K., Seiser, C., & Hertzberg, C. (2020). Vorinostat in the acute neuroinflammatory form of X-linked adrenoleukodystrophy. Annals of Clinical and Translational Neurology, 7, 639\u2013652","journal-title":"Annals of Clinical and Translational Neurology"}],"container-title":["NeuroMolecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12017-021-08660-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12017-021-08660-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12017-021-08660-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,29]],"date-time":"2022-10-29T06:56:58Z","timestamp":1667026618000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12017-021-08660-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,4]]},"references-count":118,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["8660"],"URL":"https:\/\/doi.org\/10.1007\/s12017-021-08660-4","relation":{},"ISSN":["1535-1084","1559-1174"],"issn-type":[{"value":"1535-1084","type":"print"},{"value":"1559-1174","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,4]]},"assertion":[{"value":"10 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}